Navigation Links
Vanda Pharmaceuticals Appoints Chief Financial Officer
Date:11/12/2010

ROCKVILLE, Md., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that it has named James Patrick Kelly as Senior Vice President, Chief Financial Officer, Treasurer and Secretary of the Company.

Mr. Kelly has more than 18 years of experience in financial and operating roles within the healthcare and pharmaceutical industry, most recently as Vice President, Controller at MedImmune, LLC.  He will join Vanda on December 13, 2010.

"We welcome Jim to Vanda and look forward to his financial leadership as we advance our late-stage product pipeline," said Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer of Vanda.

Mr. Kelly has been a key member of MedImmune's financial leadership team since 2006.  He joined MedImmune as Director of Sales and Marketing Finance and progressed to the role of Vice President, Controller.  Prior to MedImmune and beginning in 2000, Mr. Kelly was at Biogen Idec serving in research & development finance roles of increasing responsibility, most recently as the Director of Planning and Operations.  In that role, he was the finance leader for the global Development Organization and head of business operations for clinical functions.  While at Biogen Idec he also led the financial management of development and commercial collaborations which included 5 partners, 8 programs, 14 indications and over $1.7 billion in revenue.  From 1997-2000, he was a member of the corporate finance team at Aetna Inc. which held a critical role in mergers and acquisitions and treasury management.  During that period he participated in 11 transactions with a combined value of $20 billion.  He began his life sciences career in 1991 with Janssen Pharmaceutica, a division of Johnson & Johnson.

Mr. Kelly is a CFA charterholder and a member of the Association of Bioscience Financial Officers (ABFO).  He received his Master of Business Administration degree from Cornell University and his Bachelor of Sciences degree in Business Administration from the University of Vermont.

About Vanda Pharmaceuticals Inc:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders.  For more on Vanda, please visit http://www.vandapharma.com.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... Berkeley, and other leading institutions in announcing the launch of the Leadership ... the way animals are raised for food. , Founding members of the Leadership ...
Breaking Medicine News(10 mins):